The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...